The European Commission has approved Ranluspec, a ranibizumab biosimilar developed by Lupin and commercialized by Sandoz, for the treatment of neovascular age-related macular degeneration and several ...

Axis Securities has named Lupin, Aurobindo Pharma, Max, and Fortis as top picks, citing strong fundamentals, resilient growth drivers, and robust operational execution ...

The FDA approves biosimilar chemo infection risk treatment Filkri for cancer patients, expanding granulocyte colony-stimulating factor options.

A Japan-based biopharma company with two operating pillars: a biosimilars business (development and supply of approved ...

Lupin expects to maintain US sales at around $1 billion over the next two years, supported by a steady stream of new product launches. The company has several launches lined up across injectables, ...

Lupin's strong US portfolio, margin visibility, and regulatory progress have positioned it favourably in the eyes of analysts.

Analysts have tweaked share price targets and future outlook after some of these companies announced their December quarter results.

Lupin Ltd (BOM:500257) reports robust financial performance with significant gains in the US market and emerging markets, despite challenges in India and competitive pressures.

Vinita Gupta, Chief Executive Officer of Lupin, highlighted that exclusivity benefits in products such as Tolvaptan and Mirabegron, along with steady traction in base generics and seasonal flu ...

Aurobindo Pharma Limited recently informed that the United States Food and Drug Administration (USFDA) has completed an inspection at its Unit-VII manufacturing facility located ...

As Sandoz looks to address the “biosimilar void” created by the scores of lucrative drugs going off patent in the next decade, the generic and biosim specialist sees a multibillion-dollar opportunity ...